Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of MCI-186 in Acute Ischemic Stroke
NCT00821821Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in ischemic stroke comparing MCI-186 with Placebo Group (2 arms). Primary endpoint: Number of Participants That Experienced Adverse Events at 87 days. Started Feb 2009; status: completed.
02
Drugs
edaravone
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00821821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821821.